Taking people in Hollandia4. fázis
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial
Key facts
- Where
- 'S-Hertogenbosch, Amsterdam, Eindhoven, Enschede, Groningen, Leiden, Maastricht, Nijmegen, Rotterdam, Utrecht és Zwolle, HollandiaSee the 12 sites
- Phase
- 4. fázis
Where in Hollandia
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, HollandiaTaking people
- Amsterdam UMC StichtingAmsterdam, HollandiaTaking people
- Stichting OLVGAmsterdam, HollandiaTaking people
- Catharina Ziekenhuis StichtingEindhoven, HollandiaTaking people
- Medisch Spectrum TwenteEnschede, HollandiaTaking people
- Universitair Medisch Centrum GroningenGroningen, HollandiaTaking people
- Leiden University Medical CenterLeiden, HollandiaTaking people
- Academisch Ziekenhuis MaastrichtMaastricht, HollandiaTaking people
- Radboud universitair medisch centrum StichtingNijmegen, HollandiaTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaTaking people
- St Antonius ZiekenhuisUtrecht, HollandiaTaking people
- Isala Klinieken StichtingZwolle, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2024-519667-18-00
- Record updated
- 2026. szeptember 17.
- Original description
The primary aim of the PANENCA trial is to investigate the effect of a combined treatment with hydrocortisone, octreotide, teres patch (HOP bundle) on major complications after pancreatoduodenectomyRead full original descriptionShow less
The primary aim of the PANENCA trial is to investigate the effect of a combined treatment with hydrocortisone, octreotide, teres patch (HOP bundle) on major complications after pancreatoduodenectomy
Inclusion: Elective pancreatoduodenectomy for any indication (both minimally invasive and open); Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI; Age >18 years.
Exclusion: Concomitant use of CYP3A4 inhibitors and inducers, (see PROTOCOL CYTOCHROME P450 DRUG INTERACTION TABLE (iu.edu)); Known allergy/hypersensitivity to hydrocortisone or octreotide; Systemic fungal infection; <18 years old; Pregnant.